Literature DB >> 20192724

Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens.

Pere Domingo1, Maria Carmen Cabeza, Alain Pruvost, Juliana Salazar, Maria Del Mar Gutierrez, Maria Gracia Mateo, Joan C Domingo, Irene Fernandez, Francesc Villarroya, Jessica Muñoz, Francesc Vidal, Montserrat Baiget.   

Abstract

BACKGROUND: The link between human immunodeficiency virus/highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome (HALS) and the use of thymidine analogues has been well established. However, to our knowledge, no relationship has been proven between intracellular levels of stavudine (d4T) and HALS.
METHODS: We measured peripheral blood mononuclear cell intracellular levels of d4T-triphosphate (TP) in patients who were receiving d4T as part of their antiretroviral regimens. d4T-TP levels were determined by a validated liquid chromatography-tandem mass spectrometry assay method. The diagnosis of HALS was made in accordance with the criteria of a lipodystrophy severity grading scale. The Student t test, Pearson correlations, 1-way analysis of variance with Bonferroni correction, and stepwise logistic regression were used for statistic analyses.
RESULTS: This was a cross-sectional study. There were 33 patients: 17 with HALS and 16 without HALS. The median concentration of d4T-TP for patients with HALS was 20.60 femtomoles (fmol)/1 x 10(6) cells (interquartile range [IQR], 14.90-26.92 fmol/1 x 10(6) cells) and for patients without HALS was 13.85 fmol/1 x 10(6) cells (IQR, 8.65-20.15 fmol/1 x 10(6) cells) (P=.013). The median d4T-TP intracellular level in patients who had developed an AIDS-defining condition was 22.50 fmol/1 x 10(6) cells (IQR, 15.80-27.37 fmol/1 x 10(6) cells) and in those who had not was 14.40 fmol/1 x 10(6) cells (IQR, 10.80-20.40 fmol/1 x 10(6) cells) (P=.037). There were no statistically significant differences in d4T-TP intracellular levels with respect to the presence of metabolic syndrome, the clinical form of HALS (pure lipoatrophic vs mixed), the degree of facial lipoatrophy, the presence of hepatitis C virus infection, and the pair of nucleosides in HAART. d4T-TP levels correlated only with cumulative d4T exposure in time and dose. d4T-TP intracellular levels were independently associated with HALS (odds ratio, 1.58; 95% confidence interval, 1.08-2.32; P=.019).
CONCLUSIONS: Intracellular levels of d4T-TP are strongly associated with the development of HALS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20192724     DOI: 10.1086/651117

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.

Authors:  Pere Domingo; M Carmen Cabeza; Alain Pruvost; Ferran Torres; Juliana Salazar; M del Mar Gutierrez; M Gracia Mateo; Angels Fontanet; Irene Fernandez; Joan C Domingo; Francesc Villarroya; Francesc Vidal; Montserrat Baiget
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Replication of RYR3 gene polymorphism association with cIMT among HIV-infected whites.

Authors:  Sadeep Shrestha; Qi Yan; Gregory Joseph; Donna K Arnett; Jeremy J Martinson; Lawrence A Kingsley
Journal:  AIDS       Date:  2012-07-31       Impact factor: 4.177

3.  Subcutaneous Adipocyte Adenosine Triphosphate Levels in HIV Infected Patients.

Authors:  Greg S Gojanovich; Cecilia M Shikuma; Cris Milne; Daniel E Libutti; Dominic C Chow; Mariana Gerschenson
Journal:  AIDS Res Hum Retroviruses       Date:  2019-09-17       Impact factor: 2.205

4.  In silico study supports the efficacy of a reduced dose regimen for stavudine.

Authors:  Selwyn J Hurwitz; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2011-08-22       Impact factor: 5.970

5.  Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

Authors:  Sherwin K B Sy; Ruben Malmberg; Aoi Matsushima; Eduardo Asin-Prieto; Bernd Rosenkranz; Mark F Cotton; Hartmut Derendorf; Steve Innes
Journal:  Int J Antimicrob Agents       Date:  2015-01-19       Impact factor: 5.283

6.  Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study.

Authors:  Carla M T Fourie; Johannes M Van Rooyen; Annamarie Kruger; Michael H Olsen; Jesper Eugen-Olsen; Rudolph Schutte; Aletta E Schutte
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

7.  Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study.

Authors:  Phumla Z Sinxadi; Jan-Stefan van der Walt; Helen M McIlleron; Motasim Badri; Peter J Smith; Joel A Dave; Naomi S Levitt; Gary Maartens
Journal:  AIDS Res Ther       Date:  2010-07-14       Impact factor: 2.250

8.  Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.

Authors:  Sherwin K B Sy; Steve Innes; Hartmut Derendorf; Mark F Cotton; Bernd Rosenkranz
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

9.  Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy.

Authors:  Pere Domingo; Maria del Carmen Cabeza; Ferran Torres; Juliana Salazar; Maria del Mar Gutierrez; Maria Gracia Mateo; Esteban Martínez; Joan Carles Domingo; Irene Fernandez; Francesc Villarroya; Esteban Ribera; Francesc Vidal; Montserrat Baiget
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

10.  Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients.

Authors:  Pere Domingo; Maria Gracia Mateo; Alain Pruvost; Ferran Torres; Juliana Salazar; Maria Del Mar Gutierrez; Joan Carles Domingo; Irene Fernandez; Francesc Villarroya; Francesc Vidal; Montserrat Baiget; Oscar de la Calle-Martín
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.